Ligand Pharmaceuticals Inc LGND
Ligand Pharmaceuticals Inc (Nasdaq: LGND) is a life-science royalty company. Its next catalyst on record is Ersodetug (Rezolute): Topline data from Phase 3 study in tumor hyperinsulinism (December 2026).
Upcoming catalysts
- December 2026Ersodetug (Rezolute) — Topline data from Phase 3 study in tumor hyperinsulinism
Rezolute announced completion of enrollment in the Phase 3 study of ersodetug in tumor HI and topline data is expected mid-December 2026.
- February 2027Qtorin rapamycin (Palvella) — PDUFA target action date for NDA in microcystic lymphatic malformations
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.
Next further out: Qtorin rapamycin (Palvella) — Initiation of Phase 3 trial for cutaneous venous malformations (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Recent results and decisions
- Oct 28, 2026accepted FDA accepted for filing and granted Priority Review of the NDA for Qtorin rapamycin for microcystic LMs with PDUFA date of February 28, 2027.
The FDA accepted for filing and granted Priority Review of the New Drug Application (NDA) for Qtorin rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs).
Filing - Oct 1, 2026completed enrollment Orchestra BioMed announced full enrollment in the BACKBEAT global pivotal trial of AVIM Therapy with 330 patients randomized.
Orchestra BioMed announced it surpassed full enrollment in the BACKBEAT global pivotal trial of AVIM Therapy with 330 patients randomized, exceeding its previously announced target of 316 randomized patients.
Filing - Sep 16, 2026approval Japanese Ministry of Health, Labour and Welfare approved Ojemda for low-grade glioma harboring a BRAF mutation or fusion gene.
Ipsen announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Ojemda for low-grade glioma harboring a BRAF mutation or fusion gene.
Filing
8 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.